E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
|
E.1.1.1 | Medical condition in easily understood language |
histologically confirmed metastatic melanoma, stage IV, |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Cancer [C04] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 14.0 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10025671 |
E.1.2 | Term | Malignant melanoma stage IV |
E.1.2 | System Organ Class | 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
efficacy of the combined treatment with ipilimumab and intratumoral IL-2 based on the Disease Control Rate according to immune-related Response Criteria (irDCR) at week 12 |
|
E.2.2 | Secondary objectives of the trial |
• Tolerability according to NCI-CTCAE-Criteria (version 4) • Overall response rate (sum of irPR and irCR) at week 12 according to irRC • Overall survival after 12 months • Best overall responsei rate according to irRC (irBORR). • Overall Response Rate at week 12 and Best Overall Response Rate according to modified mWHO criteria
|
|
E.2.3 | Trial contains a sub-study | Yes |
E.2.3.1 | Full title, date and version of each sub-study and their related objectives |
Investigation of tumor-infiltrating lymphocytes, Peripheral blood mononuclear cells (PBMC) subsets, melanoma-specific T cells during treatment • Response rate of injected metastases only at week 12. • Rate of patients with substantial increase of anti-melanoma T cells in peripheral blood during treatment • Changes in T cell subsets during treatment • Changes in subsets of tumor-infiltrating lymphocytes during treatment
|
|
E.3 | Principal inclusion criteria |
• Willing and able to give written informed consent; • Histological diagnosis of malignant melanoma; • Stage IV melanoma; • At least one injectable lesions > 5 mm (longest diameter) or at least 5 injectable lesions < 5 mm. • Measurable disease. Note: lesions, which are designated for direct IL -2 injections, must not be considered in the evaluation of measurability; • Men and women, 18 years of age; • Patient must have demonstrated 1 of the following in response to at least 1 cycle of 1 or more systemic regimens: 1) relapse following an objective response (PR/CR); 2) failed to demonstrate an objective response (PR/CR); or 3) inability to tolerate treatment due to unacceptable toxicity • At least 4 weeks since treatment (chemotherapy, biochemotherapy, surgery, radiation, immunotherapy, etc.) for melanoma and recovered from any clinically significant toxicity experienced during treatment; • Life expectancy ≥3 months; • ECOG performance status of 0 or 1; • Women of childbearing potential (WOCBP) must have a negative serum or urine pregnancy test (minimum sensitivity 25 IU/L or equivalent units of HCG) within 72 hours before the start of ipilimumab; • No known active or chronic infection with HIV, Hepatitis B, or Hepatitis C; • Required values for initial laboratory tests: 1. WBC 2000/µL 2. ANC 1000/µL 3. Platelets 75000/µL 4. Hemoglobin 9 g/dL ( 8 g/dL; may be transfused) 5. Creatinine 2.0 x ULN 6. AST/ALT 2.5 x ULN ( 5 times x ULN for patients with liver metastases) 7. Bilirubin 2.0 x ULN, (except patients with Gilbert’s Syndrome, who must have a total bilirubin less than 3.0 mg/dL) • Men of fathering potential must be using an adequate method of contraception to avoid conception throughout the study and for up to 26 weeks after the last dose of investigational product in such a manner that the risk of pregnancy is minimized.
|
|
E.4 | Principal exclusion criteria |
• Any other prior malignancy from which the patient has been disease-free for less than 5 years, with the exception of adequately treated and cured basal or squamous cell skin cancer, superficial bladder cancer or carcinoma in situ of the cervix; • Ocular melanoma; mucosal melanoma • Either untreated or symptomatic central nervous system (CNS) metastases (patients with brain metastases who are identified at screening may be rescreened after the lesion(s) have been appropriately treated); • Autoimmune disease: Patients with a history of inflammatory bowel disease are excluded from this study, as are patients with a history of symptomatic autoimmune disease (e.g., rheumatoid arthritis, systemic progressive sclerosis [scleroderma], systemic lupus erythematosus, autoimmune vasculitis [e.g., Wegener’s Granulomatosis]); motor neuropathy considered of autoimmune origin (e.g., Guillain-Barre Syndrome). Patients with vitiligo may be included. • Any underlying medical or psychiatric condition, which in the opinion of the investigator will make the administration of ipilimumab hazardous or obscure the interpretation of AEs, such as a condition associated with frequent diarrhea. • Any non-oncology vaccine therapy used for prevention of infectious diseases (for up to 1 month before or after any dose of ipilimumab). • A history of prior systemic treatment with ipilimumab, CD137 agonist, CTLA 4 inhibitor, CTLA-4 agonist or IL-2 in stage IV melanoma. • Concomitant or less than 4 weeks off therapy with any of the following: interferon; other non-study immunotherapy regimens; cytotoxic chemotherapy; immunosuppressive agents; other investigation therapies; chronic use of systemic corticosteroids. • Women of childbearing potential (WOCBP), defined in Section 5.3, who: 1. are unwilling or unable to use an acceptable method of contraception to avoid pregnancy for their entire study period and for at least 26 weeks after cessation of study drug, or 2. have a positive pregnancy test at baseline, or 3. are pregnant or breastfeeding. • Subjects who are compulsorily detained for treatment of either a psychiatric or physical (e.g., infectious) illness.
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
Immune related Disease control rate (irDCR): sum of patients with an overall response irCR or irPR or irSD divided by the total number of patients, who are evaluable of efficacy. 95% confidence intervals will be provided.
|
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
|
E.5.2 | Secondary end point(s) |
Immune related Overall response rate at week 12 (irORR): sum of patients with an overall response irPR or irCR, divided by the total number of patients, who are evaluable of efficacy. 95% confidence intervals will be provided. Immune related Best overall response rate (irBORR): number of patients whose irBOR is CR or PR divided by the total number of patients, who are evaluable of efficacy. 95% confidence intervals will be provided. Response rate with regards to injected metastases only at week 12: sum of patients with CRinj or PRinj divided by the total number of patients with either CRinj, PRinj, SDinj or PDinj. 95% confidence intervals will be provided. Overall survival after 12 months: The calculation of the overall survival rate after 12 months (12 months after the first dose) will comprise all patients, who received at least one dose of study drug(s). It will be calculated using the Kaplan-Meier method. An event is defined as death from malignant melanoma. All other patients will be censored at the time point of his/her last follow-up within the context of this protocol. 95% confidence intervals for the estimated survival rate will be provided. Overall response rate at week 12 according to mWHO criteria: sum of patients with an overall response PR or CR according to mWHO criteria, divided by the total number of patients, who are evaluable of efficacy. 95% confidence intervals will be provided. Best overall response rate according to mWHO criteria: number of patients whose Best Overall Response is CR or PR according to mWHO criteria divided by the total number of patients, who are evaluable of efficacy. 95% confidence intervals will be provided. Clinical safety data will be analyzed by descriptive statistics for all patients, who received at least one dose of any investigational product within this protocol and attended at least once after dosing for adverse event assessment. The endpoints of optional translational side studies (rate of patients with substantial increase of anti-melanoma T cells in peripheral blood during treatment, changes in T cell subsets during treatment and changes in subsets of tumor-infiltrating lymphocytes) are exploratory and will only be analyzed by descriptive statistics.
|
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
week 12 and after 12 months after the first dose per patient |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | No |
E.8.1.1 | Randomised | No |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 4 |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
12 months after the first dose of the last patient enrolled into this study |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 3 |
E.8.9.1 | In the Member State concerned months | |
E.8.9.1 | In the Member State concerned days | |